Drugs / Antagon
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT04327934 Background | Dec 2017 → Jun 2022 | hypertensive disorder, polycystic ovary syndrome | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00298025 Comparator | Sep 2003 → May 2004 | — | EMD Serono | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antagon | “Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily” NCT00298025 ↗ |
| Route | Subcutaneous | “Antagon™ will be administered subcutaneously” NCT00298025 ↗ |